The global biotechnology market was worth USD 1.68 trillion in 2024 and is expected to surge around USD 3.54 Trillion by 2033, with a noteworthy CAGR of 9.18% from 2024 to 2033. The growing demand for ...

High Tide Inc. ("High Tide" or the "Company") , the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, announced today that its Canna Cabana ...

VS Mani, CFO of Glenmark Pharma, discusses the company's strong performance in FY25 with an average of Rs 1,100 crore per ...

SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth ...

All information in this presentation is as of the date presented, and BeiGene undertakes no duty to update such information unless required by law.

This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 ...

Beigene, Ltd. (NASDAQ:ONC – Free Report) – Leerink Partnrs boosted their FY2024 EPS estimates for shares of Beigene in a research report issued to clients and investors on Wednesday, February 5th.

In a report released yesterday, Kelly Shi from Jefferies reiterated a Buy rating on BeiGene (ONC – Research Report), with a price target of $286.00. Kelly Shi’s rating is based on a ...